BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported its results for the fourth quarter and full year 2008. In 2008, NPS initiated two Phase 3 registration studies – STEPS for GATTEX™ (teduglutide) in short bowel syndrome (SBS) and REPLACE for NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism. NPS also reported positive partnership progress, with Nycomed opting to share external clinical trial expenses for the STEPS study. Royalty revenue for the fourth quarter 2008 increased 30% over the fourth quarter 2007.
